Lexaria Bioscience Corp. has developed DehydraTECH, a patented drug delivery technology designed to improve oral bioavailability of various active pharmaceutical ingredients (APIs) including GLP-1 drugs and cannabinoids. The company maintains a broad patent portfolio and licenses its technology globally across pharmaceutical and consumer sectors. Despite growing revenues, Lexaria reports substantial operating losses and negative cash flows. Key risks include regulatory uncertainties, dependence on third-party collaborators, Nasdaq listing compliance challenges due to stock price issues, and the need for additional financing. Near-term prospects depend on advancing clinical trials, activating dormant licenses, and navigating regulatory and market access hurdles amid financial constraints.